ZA867771B - A method for the treatment of atherosclerosis,thrombosis and peripheral vessel disease - Google Patents

A method for the treatment of atherosclerosis,thrombosis and peripheral vessel disease

Info

Publication number
ZA867771B
ZA867771B ZA867771A ZA867771A ZA867771B ZA 867771 B ZA867771 B ZA 867771B ZA 867771 A ZA867771 A ZA 867771A ZA 867771 A ZA867771 A ZA 867771A ZA 867771 B ZA867771 B ZA 867771B
Authority
ZA
South Africa
Prior art keywords
thrombosis
atherosclerosis
treatment
vessel disease
peripheral vessel
Prior art date
Application number
ZA867771A
Inventor
Bernward Scholkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA867771B publication Critical patent/ZA867771B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The preferred angiotensin converting enzyme inhibitors have the formula I <IMAGE> in which n is 1 or 2, R, R<1>, R<2> and R<3> are identical or different and each is hydrogen or an organic radical, and R<4> and R<5> form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system. Agents containing these compounds for treating the specified diseases are also described.
ZA867771A 1985-10-15 1986-10-14 A method for the treatment of atherosclerosis,thrombosis and peripheral vessel disease ZA867771B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853536687 DE3536687A1 (en) 1985-10-15 1985-10-15 METHOD FOR TREATING ATHEROSCLEROSIS, THROMBOSIS AND PERIPHERAL VESSEL DISEASE

Publications (1)

Publication Number Publication Date
ZA867771B true ZA867771B (en) 1987-05-27

Family

ID=6283587

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA867771A ZA867771B (en) 1985-10-15 1986-10-14 A method for the treatment of atherosclerosis,thrombosis and peripheral vessel disease

Country Status (12)

Country Link
EP (1) EP0219782B1 (en)
JP (1) JPS6287524A (en)
KR (1) KR930008094B1 (en)
AT (1) ATE95064T1 (en)
AU (1) AU594711B2 (en)
CA (1) CA1320904C (en)
DE (2) DE3536687A1 (en)
DK (1) DK490486A (en)
ES (1) ES2059301T3 (en)
IE (1) IE60767B1 (en)
PT (1) PT83535B (en)
ZA (1) ZA867771B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962105A (en) * 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
DE3818245A1 (en) * 1988-05-28 1989-12-07 Hoechst Ag COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH COLD CHANNEL MODULATORS AND THEIR USE IN MEDICINAL PRODUCTS
US4931464A (en) * 1989-02-15 1990-06-05 E. R. Squibb & Sons, Inc. Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3923402A1 (en) * 1989-07-14 1991-01-17 Thera Patent Verwaltungs Gmbh USE OF ACE INHIBITORS FOR THE PROPHYLAXIS AND THERAPY OF THE CHRONIC-VENOESE INSUFFICIENCY
DE3925759A1 (en) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh USE OF ACE INHIBITORS FOR ATHEROSKLEROSEPROPHYLAXE
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
CA2040865C (en) * 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
DE69734405T2 (en) 1996-07-15 2006-08-03 Sankyo Co., Ltd. Use of CS-866 (Olmersartan) for the manufacture of a medicament for the treatment of arteriosclerosis
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470972A (en) * 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4374847A (en) * 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
SU1327787A3 (en) * 1981-11-05 1987-07-30 Хехст Аг (Фирма) Method of producing cis,endo-2-azabicyclo-(3,3,0)-octane-3-carboxylic acids or acid-additive salts thereof
DE3438545A1 (en) * 1984-10-20 1986-04-24 Merck Patent Gmbh, 6100 Darmstadt PEPTIDE

Also Published As

Publication number Publication date
IE862711L (en) 1987-04-15
AU594711B2 (en) 1990-03-15
PT83535A (en) 1986-11-01
EP0219782A3 (en) 1990-05-30
EP0219782B1 (en) 1993-09-29
AU6389086A (en) 1987-04-16
DK490486A (en) 1987-04-16
KR930008094B1 (en) 1993-08-25
ATE95064T1 (en) 1993-10-15
EP0219782A2 (en) 1987-04-29
IE60767B1 (en) 1994-08-10
DE3689099D1 (en) 1993-11-04
KR870004054A (en) 1987-05-07
DK490486D0 (en) 1986-10-14
DE3536687A1 (en) 1987-04-16
CA1320904C (en) 1993-08-03
PT83535B (en) 1989-05-31
JPS6287524A (en) 1987-04-22
ES2059301T3 (en) 1994-11-16

Similar Documents

Publication Publication Date Title
ZA867771B (en) A method for the treatment of atherosclerosis,thrombosis and peripheral vessel disease
AU6760987A (en) Method of treating alzheimer&#39;s disease
EP0237082A3 (en) Transglutaminase inhibitors
GB9020441D0 (en) New method of treatment &amp; heterocyclic compounds used therein
PH30831A (en) Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia.
DE3689853D1 (en) Use of gyrase inhibitors for the decontamination of Mycoplasma-infected cell cultures.
EG18700A (en) Process and equipment for the purification of sewages containing organic materials particularly for the effective removal of phosphorus and nitrogen
GB2182920B (en) Primary sewage sludge treatment process
IE881991L (en) Homocyclostatine and cyclostatine containing polypeptides as¹antihypertensive agents
JPS5681181A (en) Method of treating tilling pond sludge
NO862454D0 (en) PROCEDURE FOR THE TREATMENT OF PEROXYDE WHITE DISPOSAL.
CS164887A1 (en) Method of waste waters biological treatment from organical compounds and nitrogen
PL267710A1 (en) Method of cooling cokery waste waters
CS997087A1 (en) Equipment for waste waters&#39; biological treatment especially from small sources
PL265833A1 (en) Method of treating organic wastes
HUT69127A (en) Apparatous for biological treatment of sludges
PL276165A1 (en) Apparatus for biological treatment of sewages
EP0289796A3 (en) Method of treating microorganism cells containing tryptophanase or treated product thereof
CS7690A2 (en) Method of organic contamination and nitrogen and phosphorus compounds biological elimination from waste waters
PL267080A1 (en) Method of biologically treating waste waters
HU900776D0 (en) Process and technology for treatment and reutilization of sewagewater of community and thin-manure and their sludge
IT1218865B (en) PROCEDURE FOR THE DENATURATION AND INERTIZATION OF INDUSTRIAL SLUDGE
CS883388A1 (en) Method of waste waters&#39; biological treatment
JPS55149698A (en) Method of recovering sterilized sludge solid matter for reclaiming land